HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (36) Citing Articles via Google Scholar Google Scholar Articles by Sorokin, A. Articles by Kohan, D. E. Search for Related Content PubMed PubMed Citation Articles by Sorokin, A. Articles by Kohan, D. E.

INVITED REVIEW

Physiology and pathology of endothelin-1 in renal mesangium

¹Division of Nephrology, Medical College of Wisconsin, Milwaukee, Wisconsin 53226; and ²Division of Nephrology, University of Utah Health Sciences Center and Salt Lake Veterans Affairs Medical Center, Salt Lake City, Utah 84132

Mesangial cells (MCs) play a central role in the physiology and pathophysiology of endothelin-1 (ET-1) in the kidney. MCs release ET-1 in response to a variety of factors, many of which are elevated in glomerular injury. MCs also express ET receptors, activation of which leads to a complex signaling cascade with resultant stimulation of MC hypertrophy, proliferation, contraction, and extracellular matrix accumulation. MC ET-1 interacts with other important regulatory factors, including arachidonate metabolites, nitric oxide, and angiotensin II. Excessive stimulation of ET-1 production by, and activity in, MC is likely of pathogenic importance in glomerular damage in the setting of diabetes, hypertension, and glomerulonephritis. The recent introduction of ET antagonists, and possibly ET-converting enzyme inhibitors, into the clinical arena establishes the potential for new therapies for those diseases characterized by increased MC ET-1 actions. This review will examine our present understanding of how ET-1 is involved in mesangial function in health and disease. In addition, we will discuss the status of clinical trials using ET antagonists, which have only been conducted in nonrenal disease, as a background for advocating their use in diseases characterized by excessive MC-derived ET-1.

mesangial cell; cell signaling; receptor; pathophysiology

This article has been cited by other articles:

				J. M. Sasser, J. C. Sullivan, J. L. Hobbs, T. Yamamoto, D. M. Pollock, P. K. Carmines, and J. S. Pollock Endothelin A Receptor Blockade Reduces Diabetic Renal Injury via an Anti-Inflammatory Mechanism J. Am. Soc. Nephrol., January 1, 2007; 18(1): 143 - 154. [Abstract] [Full Text] [PDF]

				Y. Ohshiro, R. C. Ma, Y. Yasuda, J. Hiraoka-Yamamoto, A. C. Clermont, K. Isshiki, K. Yagi, E. Arikawa, T. S. Kern, and G. L. King Reduction of Diabetes-Induced Oxidative Stress, Fibrotic Cytokine Expression, and Renal Dysfunction in Protein Kinase C{beta}-Null Mice Diabetes, November 1, 2006; 55(11): 3112 - 3120. [Abstract] [Full Text] [PDF]

				C. M. Richter Role of endothelin in chronic renal failure--developments in renal involvement Rheumatology, October 1, 2006; 45(suppl_3): iii36 - iii38. [Abstract] [Full Text] [PDF]

				V. A. Rufanova and A. Sorokin CrkII Associates with BCAR3 in Response to Endothelin-1 in Human Glomerular Mesangial Cells. Experimental Biology and Medicine, June 1, 2006; 231(6): 752 - 756. [Abstract] [Full Text] [PDF]

				P. Daull, A. Blouin, M. Beaudoin, S. Gadbois, K. Belleville, J. Cayer, N. Berthiaume, P. Sirois, F. Nantel, A. Y. Jeng, et al. The Hemodynamic and Metabolic Profiles of Zucker Diabetic Fatty Rats Treated with a Single Molecule Triple Vasopeptidase Inhibitor, CGS 35601. Experimental Biology and Medicine, June 1, 2006; 231(6): 824 - 829. [Abstract] [Full Text] [PDF]

				T. Uchide and K. Saida Primary structure of cat preproendothelin-2 and cat renal mRNA expression of preproendothelin-1 and preproendothelin-2 in naturally occurring renal failure. Experimental Biology and Medicine, June 1, 2006; 231(6): 997 - 1000. [Abstract] [Full Text] [PDF]

				J. Ortmann, P. C. Nett, J. Celeiro, R. Hofmann-Lehmann, L. Tornillo, L. M. Terracciano, and M. Barton Downregulation of renal endothelin-converting enzyme 2 expression in early autoimmune diabetes. Experimental Biology and Medicine, June 1, 2006; 231(6): 1030 - 1033. [Abstract] [Full Text] [PDF]

				N. Dhaun, J. Goddard, and DavidJ. Webb The Endothelin System and Its Antagonism in Chronic Kidney Disease J. Am. Soc. Nephrol., April 1, 2006; 17(4): 943 - 955. [Abstract] [Full Text] [PDF]

				V. Portik-Dobos, A. K. Harris, W. Song, J. Hutchinson, M. H. Johnson, J. D. Imig, D. M. Pollock, and A. Ergul Endothelin antagonism prevents early EGFR transactivation but not increased matrix metalloproteinase activity in diabetes Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2006; 290(2): R435 - R441. [Abstract] [Full Text] [PDF]

				J. F. Reckelhoff, L. L. Yanes, R. Iliescu, L. A. Fortepiani, and J. P. Granger Testosterone supplementation in aging men and women: possible impact on cardiovascular-renal disease Am J Physiol Renal Physiol, November 1, 2005; 289(5): F941 - F948. [Abstract] [Full Text] [PDF]

				A. Zhang, G. Ding, S. Huang, Y. Wu, X. Pan, X. Guan, R. Chen, and T. Yang c-Jun NH2-terminal kinase mediation of angiotensin II-induced proliferation of human mesangial cells Am J Physiol Renal Physiol, June 1, 2005; 288(6): F1118 - F1124. [Abstract] [Full Text] [PDF]

				R. Ma, J. L. Pluznick, and S. C. Sansom Ion Channels in Mesangial Cells: Function, Malfunction, or Fiction Physiology, April 1, 2005; 20(2): 102 - 111. [Abstract] [Full Text] [PDF]